Skip to main content

Week in Review: Haohai Bio Enters $527 Million Deal for Dermatology Products

Deals and Financings   Shanghai Haohai Biological announced a $527 million agreement to develop Eirion Therapeutics' aesthetic dermatology products in China ; Arctic Vision of Shanghai completed a $100 million Series B financing led by Loyal Valley Capital to develop ophthalmology therapies; CASI Pharma, a Maryland-Beijing company, acquired China rights to a cancer drug developed by Cleave Therapeutics in an $85 million agreement; Shanghai Delonix Bioworks closed a $14 million seed financing for its synthetic biology vaccines with an initial goal of overcoming anti-microbial resistance; WuXi Biologics of Shanghai out-licensed a panel of mAbs to Exelixis aimed at a specific target for an upfront and milestone payments; Shanghai 's AlphaBio in-licensed Asia rights to Wugen's novel universal natural killer and T-cell therapies for cancer; I-Mab, a Shanghai biopharma, formed two new discovery collaborations, one with the EU's Complix and the other with Shanghai Affinity Biopharma; Yangzhou Uni-Bio partnered with Singapore 's DotBio to co-develop next-gen, best-in-class synthetic retinal therapeutics; COVID-19 Pandemic   Suzhou Kintor Pharma reported that its androgen receptor agonist reduced mortality risk in newly hospitalized COVID-19 patients by 92%; Trials and Approvals China Oncology Focus, a Lee's Pharm affiliate, was approved to start a China Phase III trial of its PD-L1 antibody as a first-line treatment for NSCLC; Jiangsu Alphamab Oncology was approved to start a US Phase II trial of its PD-L1/CTLA-4 bispecific antibody to treat thymic carcinoma, a rare disease; Shanghai Gannex Pharma, a subsidiary of Hangzhou 's Ascletis, reported positive topline results from a China Phase II trial of its NASH treatment; BeiGene of Beijing started a global Phase I trial of a novel HPK1 inhibitor in patients with advanced solid tumor cancers. Stock Symbols: (HK: 6826; SHA: 688366) (NSDQ: CASI) (HK: 2269) (NSDQ: IMAB) (HK: 00690) (HK: 9939) (HK: 950) (HK: 9966) (HK:1672) (NSDQ: BGNE; HK: 06160) Share this with colleagues: // //
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.